Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients.
Perez, V, Sanchez-Escuredo A, et al.European Journal of Pharmacology 2013; 709(1-3):72-9.
Aims
To investigate the pleiotropic effects of paricalcitol on bone mineral parameters, kidney function and inflammatory status of kidney transplant patients.
Interventions
The paricalcitol group were administered with oral paricalcitol at 1µg/day and the control group did not receive paricalcitol.
Participants
52 stable kidney transplant recipients receiving a triple immunosuppressive regime of prednisone, calcineurin inhibitor and mycophenolate mofetil.
Outcomes
The outcomes of the study include biochemical variables (25-hydroxyvitamin D, intact parathyroid hormone, alkaline phosphatase, albumin corrected calcium, bone mineral density, modification of diet in renal disease formula and c-reactive protein) and proteomic analysis.
Follow-up
12 months.
CET Conclusions
This is a careful study of the effect the administration of paricalcitol (a selective Vitamin D receptor activator ) in stable renal transplant recipients. Paricalcitol ameliorated mineral bone loss and also in their proteomic analysis suggested that there may have been other additional benefits due to immunomodulatory effects via the kallikrein-kinin and complement systems.
Data analysis
Per protocol analysis
Trial registration
Not reported.